Ionis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Ionis Pharmaceuticals's earnings have been declining at an average annual rate of -49.8%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been declining at an average rate of 5.6% per year.
Key information
-49.8%
Earnings growth rate
-49.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -5.6% |
Return on equity | -129.8% |
Net Margin | -49.5% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
Jun 15Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Apr 06Ionis Pharmaceuticals: Finding Financial Value In Biotech Research
Mar 27Ionis: At A Show-Me Crossroads
Mar 14Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates
Feb 25Revenue & Expenses Breakdown
How Ionis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 777 | -385 | 220 | 0 |
31 Dec 23 | 788 | -366 | 213 | 0 |
30 Sep 23 | 615 | -409 | 210 | 0 |
30 Jun 23 | 631 | -309 | 174 | 0 |
31 Mar 23 | 576 | -329 | 162 | 0 |
31 Dec 22 | 587 | -270 | 150 | 0 |
30 Sep 22 | 875 | 7 | 141 | 0 |
30 Jun 22 | 849 | -28 | 137 | 0 |
31 Mar 22 | 841 | -4 | 148 | 0 |
31 Dec 21 | 810 | -29 | 186 | 0 |
30 Sep 21 | 661 | -608 | 207 | 0 |
30 Jun 21 | 688 | -550 | 245 | 0 |
31 Mar 21 | 708 | -495 | 272 | 0 |
31 Dec 20 | 729 | -444 | 354 | 0 |
30 Sep 20 | 933 | 94 | 299 | 0 |
30 Jun 20 | 940 | 145 | 290 | 0 |
31 Mar 20 | 959 | 169 | 293 | 0 |
31 Dec 19 | 1,123 | 281 | 287 | 0 |
30 Sep 19 | 821 | 433 | 269 | 0 |
30 Jun 19 | 799 | 402 | 278 | 0 |
31 Mar 19 | 752 | 366 | 269 | 0 |
31 Dec 18 | 600 | 277 | 245 | 0 |
30 Sep 18 | 575 | -41 | 224 | 0 |
30 Jun 18 | 548 | -38 | 182 | 0 |
31 Mar 18 | 543 | 9 | 138 | 0 |
31 Dec 17 | 514 | 19 | 108 | 0 |
30 Sep 17 | 507 | 42 | 81 | 0 |
30 Jun 17 | 499 | 52 | 64 | 0 |
31 Mar 17 | 426 | -15 | 52 | 0 |
31 Dec 16 | 373 | -60 | 49 | 0 |
30 Sep 16 | 238 | -184 | 44 | 0 |
30 Jun 16 | 176 | -227 | 42 | 0 |
31 Mar 16 | 258 | -134 | 40 | 0 |
31 Dec 15 | 284 | -88 | 37 | 0 |
30 Sep 15 | 317 | 14 | 31 | 0 |
30 Jun 15 | 312 | 23 | 27 | 0 |
31 Mar 15 | 249 | -24 | 23 | 0 |
31 Dec 14 | 214 | -39 | 20 | 0 |
30 Sep 14 | 172 | -94 | 18 | 0 |
30 Jun 14 | 151 | -92 | 17 | 0 |
31 Mar 14 | 132 | -90 | 16 | 0 |
31 Dec 13 | 147 | -61 | 15 | 0 |
30 Sep 13 | 125 | -39 | 13 | 0 |
30 Jun 13 | 113 | -52 | 10 | 0 |
Quality Earnings: IONS is currently unprofitable.
Growing Profit Margin: IONS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IONS is unprofitable, and losses have increased over the past 5 years at a rate of 49.8% per year.
Accelerating Growth: Unable to compare IONS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IONS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: IONS has a negative Return on Equity (-129.76%), as it is currently unprofitable.